Cationic Steroid Antimicrobial Compositions and Methods of Use

A method for treating a subject in need of treatment for herpesviridae (HV) infection or pathogenesis, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to treat the subject for the herpesviridae (HV) infection or pathogenesis.

A method for decreasing susceptibility or inhibiting herpesviridae (HV) reactivation from latency in a subject, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to decrease susceptibility or inhibit herpesviridae (HV) reactivation from latency in the subject.

A method for decreasing or inhibiting herpesviridae (HV) infection of a cell or herpesviridae (HV) reactivation from latency, in vitro or in vivo, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to inhibit herpesviridae (HV) infection of the cell.

A method for providing a subject with protection against herpesviridae (HV) infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-1, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to provide the subject with protection against the herpesviridae (HV) infection or pathogenesis.

A method for treating a subject in need of treatment for herpesviridae (HV) infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to treat the subject for the herpesviridae (HV) infection or pathogenesis.

A method for decreasing susceptibility or inhibiting herpesviridae (HV) reactivation from latency in a subject, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease susceptibility or inhibit herpesviridae (HV) reactivation from latency of the subject.

A method for reducing, decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms or pathologies associated with or caused by herpesviridae (HV) infection or pathogenesis, or reactivation of herpesviridae (HV) from latency, in a subject, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease, inhibit, ameliorate or prevent onset, severity, duration, progression, frequency or probability of one or more symptoms or pathologies associated with or caused by herpesviridae (HV) infection or pathogenesis, or reactivation of herpesviridae (HV) from latency in the subject.

A method for identifying a candidate agent for treating a subject for an HV infection or pathogenesis, or reactivation from latency, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with HV and ascertaining whether the test agent inhibits HV infection or pathogenesis, or reactivation from latency, wherein a test agent identified as inhibiting HV infection or pathogenesis or reactivation from latency is a candidate agent for treating a subject for HV infection or pathogenesis.

A method for identifying a candidate agent for decreasing susceptibility or inhibiting HV reactivation from latency, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with HV and ascertaining whether the test agent decreases susceptibility or inhibits HV reactivation from latency, wherein a test agent identified as decreasing susceptibility or inhibiting HV reactivation from latency is a candidate agent for decreasing susceptibility or inhibiting HV reactivation from latency.

A method for identifying a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms or pathologies caused by or associated with HV infection or pathogenesis or reactivation from latency comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) administering said test agent to a subject infected with or exposed to HV and ascertaining whether the test agent decreases, inhibits, ameliorates or prevents onset, severity, duration, progression, frequency or probability of one or more symptoms or pathologies associated with or caused by HV infection or pathogenesis, or reactivation from latency, wherein a test agent identified is a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms or pathologies associated with or caused by HV infection or pathogenesis or reactivation from latency.